BOSTON — Oct. 18, 2016 — David J. Dykeman and Eric D. Hargan, shareholders with global law firm Greenberg Traurig, LLP, will present at the American College of Surgeons’ (ACS) Clinical Congress, Oct. 16-20, 2016 at the Washington D.C. Convention Center. The ACS Clinical Congress provides education and training opportunities for surgeons, residents, medical students, and surgical team members.
On Oct. 19, Dykeman and Hargan will speak at ACS’ one-day program, “Innovation and Invention in Surgery,” which will outline the process of developing, protecting, funding, and commercializing innovations and inventions in surgery. From 11 a.m. - Noon, Dykeman, patent attorney, co-chair of Greenberg Traurig’s global Life Sciences & Medical Technology Group, and co-chair of the firm’s Intellectual Property (IP) Group in Boston, will present “Intellectual Property Considerations for Surgeons.” From 1– 2p.m., Hargan, a shareholder in the firm’s Health & FDA Business Practice in Chicago, will discuss “Regulatory Considerations, Clinical Trials and the FDA.”
With 20 years of experience in patents, IP, and licensing, Dykeman focuses his practice on securing strategic worldwide IP protection and related business strategy for high-tech clients, with particular experience in medical devices, life sciences, biotechnology, and healthcare IT. Dykeman is the founding co-chair of the American Bar Association’s (ABA) Medical Devices Committee and serves on the Editorial Advisory Board of Medical Device + Diagnostic Industry (MD+DI) Magazine. An accomplished author and a speaker on medical devices and life sciences IP, Dykeman was honored as a “Life Science Star” by LMG Life Sciences, and was named one of the Top 250 Patent and Technology Licensing Practitioners in the world by Intellectual Asset Management (IAM) Magazine.
Hargan focuses his practice on transactions, health care regulations, and government relations. Previously, Hargan served in the position of Deputy Secretary of the U.S. Department of Health and Human Services. He also served as Regulatory Policy Officer of the Department, overseeing the development and approval of all HHS, CMS, and FDA regulations and significant guidance. Hargan has spoken widely and been published both in the U.S. and overseas on health-related topics, including Medicare and Medicaid reform, health law, medical device and biologics regulation, food safety, vaccines, quarantine, public health preparedness, and pandemic influenza. He was named a “Life Science Star” by LMG Life Sciences (2012-2016).
About Greenberg Traurig’s Life Sciences & Medical Technology Group
Greenberg Traurig’s Life Sciences & Medical Technology Group advises clients ranging from startups to large multinational public companies to leading research institutions. The group’s attorneys work closely with clients, providing innovative legal counsel to help them achieve their objectives – from discovery through commercialization and product marketing.
About Greenberg Traurig, LLP
Greenberg Traurig, LLP (GTLaw) has more than 2,000 attorneys in 38 offices in the United States, Latin America, Europe, Asia and the Middle East and is celebrating its 50th anniversary. One firm worldwide, GTLaw has been recognized for its philanthropic giving, was named the largest firm in the U.S. by Law360 in 2017, and among the Top 20 on the 2016 Am Law Global 100. Web: www.gtlaw.com Twitter: @GT_Law.